Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations"
The large number of drug candidates with poor dissolution characteristics seen in the past decade, has fostered interest in so-called "enabling formulations", i.e., formulations which shall make such drugs bio-available. Development of enabling formulations is currently being guided by the...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 April 2013
|
| In: |
European journal of pharmaceutical sciences
Year: 2013, Jahrgang: 50, Heft: 1, Pages: 8-16 |
| ISSN: | 1879-0720 |
| Online-Zugang: |
|
| Verfasserangaben: | Stephen Timothy Buckley, Kerstin Julia Frank, Gert Fricker, Martin Brandl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1741217202 | ||
| 003 | DE-627 | ||
| 005 | 20230428021745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201126s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejps.2013.04.002 |2 doi | |
| 035 | |a (DE-627)1741217202 | ||
| 035 | |a (DE-599)KXP1741217202 | ||
| 035 | |a (OCoLC)1341382401 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Buckley, Stephen Timothy |e VerfasserIn |0 (DE-588)117136833X |0 (DE-627)104051703X |0 (DE-576)51372057X |4 aut | |
| 245 | 1 | 0 | |a Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations" |c Stephen Timothy Buckley, Kerstin Julia Frank, Gert Fricker, Martin Brandl |
| 264 | 1 | |c 11 April 2013 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.11.2020 | ||
| 520 | |a The large number of drug candidates with poor dissolution characteristics seen in the past decade, has fostered interest in so-called "enabling formulations", i.e., formulations which shall make such drugs bio-available. Development of enabling formulations is currently being guided by the following (simplified) hypothesis: If a poorly soluble drug (BCS class II drug) can be transferred into a solubilized state, one can achieve an absorption profile close to that of a soluble drug (BCS class I drug). Thus, formulation development typically endeavors to achieve the most robust solubility enhancement. Here we critically review both common in vitro approaches and experimental data available in literature pertaining to the solubility and permeability of poorly soluble drugs from enabling formulations, and discuss their interplay. Recent in vitro data indicate, that commonly employed surfactants as well as endogenous surfactants present in the intestine, although enhancing drug solubility, mostly hamper drug permeation. Mechanistic studies demonstrate a direct correlation between passive transcellular diffusion and the concentration of molecularly dissolved drug. The latter may be reduced due to partitioning into micelles or other solubilizing carriers, but enhanced in supersaturating formulations. We conclude thus that biopharmaceutical assessment approaches that rely on the amount of molecularly dissolved drug should guide us towards successful enabling formulations. | ||
| 650 | 4 | |a Absorption | |
| 650 | 4 | |a active pharmaceutical ingredient | |
| 650 | 4 | |a amorphous solid dispersion | |
| 650 | 4 | |a API | |
| 650 | 4 | |a ASD | |
| 650 | 4 | |a BCRP | |
| 650 | 4 | |a BCS | |
| 650 | 4 | |a Bile Acids and Salts | |
| 650 | 4 | |a Biological Availability | |
| 650 | 4 | |a Biopharmaceutical Classification Scheme | |
| 650 | 4 | |a Biopharmaceutics | |
| 650 | 4 | |a breast cancer resistant protein | |
| 650 | 4 | |a Chemistry, Pharmaceutical | |
| 650 | 4 | |a CMC | |
| 650 | 4 | |a critical micelle concentration | |
| 650 | 4 | |a CsA | |
| 650 | 4 | |a cyclosporin A | |
| 650 | 4 | |a Excipients | |
| 650 | 4 | |a FaSSIF | |
| 650 | 4 | |a fasted state simulated intestinal fluid | |
| 650 | 4 | |a fed state simulated intestinal fluid | |
| 650 | 4 | |a FeSSIF | |
| 650 | 4 | |a Gastrointestinal | |
| 650 | 4 | |a GI | |
| 650 | 4 | |a Hank’s buffered salt solution | |
| 650 | 4 | |a HBSS | |
| 650 | 4 | |a Micelle | |
| 650 | 4 | |a MRP | |
| 650 | 4 | |a multidrug resistance-related protein | |
| 650 | 4 | |a p-Glycoprotein | |
| 650 | 4 | |a p-GP | |
| 650 | 4 | |a Permeability | |
| 650 | 4 | |a Pharmaceutical Preparations | |
| 650 | 4 | |a Phospholipids | |
| 650 | 4 | |a self nanoemulsifying drug delivery system | |
| 650 | 4 | |a SNEDDS | |
| 650 | 4 | |a Solubility | |
| 650 | 4 | |a Solubilization | |
| 650 | 4 | |a SSDS | |
| 650 | 4 | |a supersaturating drug delivery systems | |
| 650 | 4 | |a Surface-Active Agents | |
| 650 | 4 | |a TEER | |
| 650 | 4 | |a transepithelial electrical resistance | |
| 700 | 1 | |a Frank, Kerstin J. |e VerfasserIn |0 (DE-588)1042228116 |0 (DE-627)768470552 |0 (DE-576)39378441X |4 aut | |
| 700 | 1 | |a Fricker, Gert |d 1956- |e VerfasserIn |0 (DE-588)1042227675 |0 (DE-627)768469465 |0 (DE-576)393783464 |4 aut | |
| 700 | 1 | |a Brandl, Martin |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmaceutical sciences |d New York, NY [u.a.] : Elsevier, 1993 |g 50(2013), 1, Seite 8-16 |h Online-Ressource |w (DE-627)300897308 |w (DE-600)1483522-8 |w (DE-576)094142033 |x 1879-0720 |7 nnas |a Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations" |
| 773 | 1 | 8 | |g volume:50 |g year:2013 |g number:1 |g pages:8-16 |g extent:9 |a Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations" |
| 951 | |a AR | ||
| 992 | |a 20201126 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 1042227675 |a Fricker, Gert |m 1042227675:Fricker, Gert |d 160000 |d 160100 |e 160000PF1042227675 |e 160100PF1042227675 |k 0/160000/ |k 1/160000/160100/ |p 3 | ||
| 998 | |g 1042228116 |a Frank, Kerstin J. |m 1042228116:Frank, Kerstin J. |p 2 | ||
| 999 | |a KXP-PPN1741217202 |e 3813448010 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Biopharmaceutical classification of poorly soluble drugs with respect to \"enabling formulations\"","title_sort":"Biopharmaceutical classification of poorly soluble drugs with respect to \"enabling formulations\""}],"language":["eng"],"id":{"doi":["10.1016/j.ejps.2013.04.002"],"eki":["1741217202"]},"physDesc":[{"extent":"9 S."}],"note":["Gesehen am 26.11.2020"],"relHost":[{"title":[{"title":"European journal of pharmaceutical sciences","subtitle":"official journal of the European Federation for Pharmaceutical Sciences","title_sort":"European journal of pharmaceutical sciences"}],"part":{"volume":"50","text":"50(2013), 1, Seite 8-16","year":"2013","extent":"9","pages":"8-16","issue":"1"},"language":["eng"],"pubHistory":["1.1993 -"],"id":{"issn":["1879-0720"],"zdb":["1483522-8"],"eki":["300897308"]},"disp":"Biopharmaceutical classification of poorly soluble drugs with respect to \"enabling formulations\"European journal of pharmaceutical sciences","physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 25.05.2020","Ungezählte Beil.: Supplement"],"titleAlt":[{"title":"Pharmaceutical sciences"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisherPlace":"New York, NY [u.a.]","dateIssuedDisp":"1993-","publisher":"Elsevier","dateIssuedKey":"1993"}],"recId":"300897308"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1741217202","origin":[{"dateIssuedDisp":"11 April 2013","dateIssuedKey":"2013"}],"person":[{"display":"Buckley, Stephen Timothy","role":"aut","given":"Stephen Timothy","family":"Buckley"},{"display":"Frank, Kerstin J.","role":"aut","given":"Kerstin J.","family":"Frank"},{"display":"Fricker, Gert","role":"aut","given":"Gert","family":"Fricker"},{"display":"Brandl, Martin","role":"aut","given":"Martin","family":"Brandl"}],"name":{"displayForm":["Stephen Timothy Buckley, Kerstin Julia Frank, Gert Fricker, Martin Brandl"]}} | ||
| SRT | |a BUCKLEYSTEBIOPHARMAC1120 | ||